SCHEMBL10330495

SCHEMBL10330495

CC[N+]1(C)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142703 0.93
SCHEMBL372419 0.90
Fluoride Ion SCHEMBL1996850 0.90
Fluoride SCHEMBL19181824 0.90
SCHEMBL7607070 0.90 KDM4E (0.44)
SCHEMBL2866854 0.90 KDM4E (0.44)
Bromide SCHEMBL384403 0.90
Hydrochloric Acid SCHEMBL556790 0.90
SCHEMBL30395307 0.90
Iodide SCHEMBL1681443 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120181668-A1 INK JET PRINTABLE ETCHING INKS AND ASSOCIATED PROCESS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-07-19 US disclosed
WO-2011032629-A1 INK JET PRINTABLE ETCHING INKS AND ASSOCIATED PROCESS MERCK PATENT GMBH (DE) 2011-03-24 WO disclosed
US-7910729-B2 Effective agents for trapping and indentifying free radical species and find use as efficient antioxidants in physicochemical and biological systems; treatment or prevention of oxidative, ischemic, ischemia/reperfusion-related and chemokine-mediated conditions THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2011-03-22 US disclosed
US-7671047-B2 Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-03-02 US disclosed
US-7579339-B2 Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-08-25 US disclosed
US-20080274947-A1 Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-11-06 US disclosed
US-7407938-B2 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-08-05 US disclosed
US-20080167474-A1 Azulenyl Nitrone Spin Trapping Agents, Methods of Making and Using Same FLORIDA INTERNATIONAL UNIVERSITY (US) 2008-07-10 US disclosed
US-7390790-B2 Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-06-24 US disclosed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
US-20070043017-A1 Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use SANOFI-AVENTIS DEUTSCHLAND GMBH 2007-02-22 US disclosed
US-20070037787-A1 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, SANOFI-AVENTIS DEUTSCHLAND GMBH 2007-02-15 US disclosed
US-7176194-B2 Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-02-13 US disclosed